BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 211,493 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 764,520 shares of the biopharmaceutical company's stock after acquiring an additional 211,493 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.06% of Gilead Sciences worth $64,097,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of GILD. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its position in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $33,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and raised their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Wolfe Research initiated coverage on Gilead Sciences in a research note on Friday, November 15th. They set an "outperform" rating and a $110.00 price target on the stock. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research report on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $95.41.

Gilead Sciences Trading Up 1.4 %

NASDAQ GILD opened at $89.84 on Friday. The business's fifty day moving average is $87.28 and its 200-day moving average is $76.61. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market capitalization of $111.96 billion, a price-to-earnings ratio of 998.22, a PEG ratio of 2.72 and a beta of 0.17. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. Gilead Sciences's revenue was up 7.0% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.43%. Gilead Sciences's payout ratio is 3,422.22%.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.